PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33284947-4	2020	The 5 analyzed proteins involved in lenalidomide"s mode of action were associated with time to progression (TTP); low levels of cereblon and IRF4 protein and high levels of Ikaros, AGO2, and Aiolos were significantly associated with shorter TTP.	Lenalidomide	36-48	argonaute RISC catalytic component 2	Homo sapiens	181-185	
27142104-6	2016	Upon treatment of IMiD-sensitive MM cells with lenalidomide, the steady-state levels of cereblon were significantly increased, whereas levels of AGO2 were significantly decreased.	Lenalidomide	47-59	argonaute RISC catalytic component 2	Homo sapiens	145-149	
29788898-13	2019	Lenalidomide decreases expression of protein argonaute-2, which binds to cereblon.	Lenalidomide	0-12	argonaute RISC catalytic component 2	Homo sapiens	37-56	
30111438-7	2018	Lenalidomide can also play a role in multiple myeloma(MM) cells by modulating miRNA levels and CRBN binding to downstream protein AGO2 expression.	Lenalidomide	0-12	argonaute RISC catalytic component 2	Homo sapiens	130-134